Worldwide demand for novel drug delivery systems (NDDS) is predicted to surge at a CAGR of 6.6% from 2022 to 2027. At present, the global novel drug delivery systems market enjoys a valuation of US$ 62.5 billion and is anticipated to climb to a market size of US$ 86 billion by the end of 2027. Oral drug delivery systems are projected to be extremely popular over the coming years owing to their ease of administration and the increasing patient-centric approach of the healthcare sector.
The offer in this portion accompanies many open doors including fabricating items, appropriation, retail, and showcasing administrations. Broad rounds of essential and far reaching optional exploration have been utilized by the examiners at Fact.MR to show up at different assessments and projections for Demand of Novel Drug Delivery Systems (NDDS) Market both at worldwide and provincial levels.
Download a Sample Copy of This Report: –https://www.factmr.com/connectus/sample?flag=S&rep_id=7604?PJ
Market Players: –
- AstraZeneca PLC
- Boston Scientific
- Genzyme Co.
- Bayer AG
- Novartis AG
- Pfizer Inc.
- Sanofi SA
- Tolmar
- GlaxoSmithKline PLC
- Johnson & Johnson
- Astellas
- Aspen
- Lupin
- Breckenridge Pharmaceuticals
- Shire
- Galen
- 3M Company
- Merck & Co. Inc.
- Teva Pharmaceuticals Industries Limited
- Abbott Laboratories
Competitive Landscape
Key companies in the novel drug delivery systems market are expected to bolster their focus on the launch of new and modern drug delivery systems equipped with advanced technologies.
- In June 2022, Gulfic Biosciences Ltd., an innovative pharmaceutical company, announced the launch of a new drug delivery system. The new drug delivery system technology was developed by Gulfic and its French counterpart at an affordable price. The new system is called Dual Chamber Bags (DCB).
- In May 2022, Jabil Healthcare, a leading name in the healthcare industry, announced the launch of a reusable drug delivery device with a broader spectrum of applications. The Qfinity Autoinjector Platform will be available at lower costs than its market alternatives and is expected to further bolster the sustainability trend in the drug delivery industry owing to its reusable nature.
NDDS market players are also expected to eye acquisitions, partnerships, and mergers to enhance their business scope and expand their market presence across the world.
- Bayer, a German biotechnology and pharmaceutical organization, in August 2021, announced the acquisition of Vividion Therapeutics to strengthen its portfolio of novel drug discovery platforms. The acquisition was valued at US$ 1.5 billion.
- In June 2022, Accord Biopharma and EVERSANA partnered to launch the CAMCEVI (leuprolide) 42mg injection emulsion that is expected to be used for the treatment of prostate cancer in adults.
Key Segments of NDDS Industry Research
- By Route :
- Oral Drug Delivery Systems
- Injectable Drug Delivery Systems
- Pulmonary Drug Delivery Systems
- Transdermal Drug Delivery Systems
- Others
- By Mode :
- Targeted Drug Delivery Systems
- Controlled Drug Delivery Systems
- Modulated Drug Delivery Systems
How Fact.MR Assists in Making Strategic Moves?
The data provided in the Novel Drug Delivery Systems (NDDS) Market report offers comprehensive analysis of important industry trends. Industry players can use this data to strategize their potential business moves and gain remarkable revenues in the upcoming period.
The report covers the price trend analysis and value chain analysis along with analysis of diverse offering by market players. The main motive of this report is to assist enterprises to make data-driven decisions and strategize their business moves.